knowing01 published DeepEvidence, a deep research agent published in July 2026 by Wang et al. in Nature Machine Intelligence.

𝗗𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗲𝘀 𝗺𝗼𝗿𝗲 𝗱𝗮𝘁𝗮 𝘁𝗵𝗮𝗻 𝗲𝘃𝗲𝗿, yet much of it remains fragmented and overlooked when decisions are made, leading to higher risk and uncertainty. At knowing01, we help biotechs make smarter pipeline decisions by unlocking the full power of molecular data. Our 𝗠𝘂𝗹𝘁𝗶𝗼𝗺𝗶𝗰𝘀𝗔𝗜 𝗖𝗲𝗹𝗹𝗺𝗮𝗽 technology, powered by over a decade of knowledge graph expertise, contextualizes molecular data across all biological types. This means 𝗰𝗹𝗲𝗮𝗿𝗲𝗿 𝘁𝗮𝗿𝗴𝗲𝘁 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻, 𝘀𝗺𝗮𝗿𝘁𝗲𝗿 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻, and 𝘀𝗵𝗮𝗿𝗽𝗲𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘀𝘁𝗿𝗮𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻. We help teams unlock up to 𝟴𝘅 𝗺𝗼𝗿𝗲 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗮𝘁𝗮 and accelerate 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲𝘀 𝗯𝘆 𝘂𝗽 𝘁𝗼 𝟲𝟬%. The outcome isn’t just better science; it’s better communication to strengthen internal alignment and present higher-quality, data-backed rationales to boards and investors. The future of medicine depends on making better use of the data we already have. 𝗧𝗵𝗮𝘁’𝘀 𝗼𝘂𝗿 𝗺𝗶𝘀𝘀𝗶𝗼𝗻, 𝗮𝗻𝗱 𝘄𝗲’𝗱 𝗹𝗼𝘃𝗲 𝘆𝗼𝘂 𝘁𝗼 𝗷𝗼𝗶𝗻 𝘂𝘀. --- Under the hood – our core technology combines knowledge graphs, machine learning (ML) and artificial intelligence (AI) to effortlessly establish billions of links in Big Data, revealing insight from information. --- Behind the scenes – knowing01's team combines a strong vision with proven expertise in research, deep tech, software and commercial experience. We commercialise IP from Helmholtz Munich, Germany.

Founded 2020